Dr. Hutchings on Subgroup Analysis of ECHELON-1 in Hodgkin Lymphoma

Video

Martin Hutchings, MD, PhD, staff specialist, Department of Hematology, Finsen Centre, National Hospital, Copenhagen University Hospital, discusses a subgroup analysis of the ECHELON-1 study in Hodgkin lymphoma.

Martin Hutchings, MD, PhD, staff specialist, Department of Hematology, Finsen Centre, National Hospital, Copenhagen University Hospital, discusses a subgroup analysis of the ECHELON-1 study in Hodgkin lymphoma.

In March 2018, the FDA approved brentuximab vedotin (Adcetris) for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma based on findings from the phase III ECHELON-1 study. Brentuximab vedotin plus doxorubicin (Adriamycin), vinblastine, and dacarbazine (A+AVD) demonstrated superior progression-free survival (PFS) compared with standard doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

Findings from the subgroup analysis of this study showed that when given in the frontline setting, A+AVD elicits a more favorable median PFS for patients with high-risk disease, which was defined as stage IV disease, ≥1 extranodal disease sites, or having an International Prognostic Score of 4 to 7. Results suggest that high-risk patients may derive greater benefit with A+AVD as opposed to ABVD.

Related Videos
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD